Pouruchis Bhiwandiwalla
Gynecology · Raleigh, NCNPI 1376576967
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $123,475 of the $157,688 with a category attached, or 78.3%. AbbVie accounts for 95.9% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $86,884 and has fallen 100.0% since, to $17 in 2024. Among gynecology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 186 payments — averaging $847.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$151K
- Astellas Pharma US Inc$5K
- Exeltis, USA Inc.$631
- Mayne Pharma Commercial LLC$256
- Scynexis, Inc.$32
- Myovant Sciences Inc.$30
- plus $106 from 6 others
Across 334 payments — averaging $6303.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$815K
- Mylan Inc.$479K
- Organon$389K
- Medicines360$113K
- Evofem Biosciences, Inc.$76K
- Bayer$58K
- plus $175K from 11 others
What the payments were for
- Consulting fees$5000%
- Speaking & faculty fees$123,47578%
- Travel & lodging$28,74918%
- Food & beverage$4,8533%
- Education$1110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 161 | $151,252 |
| Astellas Pharma US Inc | 4 | $5,381 |
| Exeltis, USA Inc. | 3 | $631 |
| Mayne Pharma Commercial LLC | 9 | $256 |
| Scynexis, Inc. | 1 | $32 |
| Myovant Sciences Inc. | 2 | $30 |
| Lupin Inc. | 1 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Organon | 1 | $17 |
| Duchesnay USA Incorporated | 1 | $16 |
| Pfizer | 1 | $15 |
| Avion Pharmaceuticals | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Orilissa$124,868
- ORIAHNN$42,640
- Veozah$5,266
- SELECT-OB PLUS DHA$615
- Slynd$615
- NEXTSTELLIS$124
- Skyrizi$101
How this compares
$157,688 in reported general payments places this provider in the 95th percentile of 90 gynecology providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PremarinEstrogens, Conjugated | 17 | $8,131 |
| Estradiol | 16 | $1,264 |
| ValacyclovirValacyclovir Hcl | 15 | $646 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPremarin | $15 | $8,13117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 90 gynecology providers in North Carolina.
Other gynecology in Raleigh
- Jerome GardnerRaleigh$99K
- Lisa RobertsRaleigh$6K
- Marianna LawRaleigh$3K
- James CarrRaleigh$3K
- Rosemarie NewmanRaleigh$3K
- Andrea TorsoneRaleigh$1K
- Suzanne KaminskiRaleigh$719
- Elizabeth Roede BarbeeRaleigh$622
- Lorena BenavidesRaleigh$513
- Sarah MoustafaRaleigh$399
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.